血尿治療の世界市場 - 2022年～2029年

当レポートでは、世界の血尿治療市場について調査し、市場の概要とともに、タイプ別、疾患タイプ別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 血尿治療市場の調査手法と範囲

第2章 血尿治療市場-市場の定義と概要

第3章 血尿治療市場-エグゼクティブサマリー

• タイプ別、市場内訳
• 疾患タイプ別、市場内訳
• エンドユーザー別、市場内訳
• 地域別、市場内訳

第4章 血尿治療市場-市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 血尿治療市場-業界分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ

第6章 血尿治療市場-COVID-19分析

第7章 血尿治療市場-タイプ別

• イントロダクション
• 市場規模分析、および前年比成長分析（％）、タイプ別
• 市場魅力指数、タイプ別
  • 薬物
  • 治療

第8章 血尿治療市場-疾患タイプ別

• イントロダクション
• 市場規模分析、および前年比成長分析（％）、疾患タイプ別
• 市場魅力指数、疾患タイプ別
  • 顕微鏡的血尿
  • 肉眼的血尿

第9章 血尿治療市場-エンドユーザー別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、エンドユーザー別
  • 市場魅力指数、エンドユーザー別
• 病院
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• 専門クリニック
• その他

第10章 血尿治療市場-地域別

• イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）、地域別
  • 市場魅力指数、地域別
• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第11章 血尿治療市場-競合情勢

• 主な発展と戦略
• 企業シェア分析
• 製品のベンチマーク

第12章 血尿治療市場-企業プロファイル概要

• Teva Pharmaceuticals Industries Ltd.
• Johnson & Johnson
• Cipla Ltd.
• F.Hoffmann La Roche Ltd.
• Merck & Co.
• Pfizer Inc.
• Aurobindo Pharma USA
• Zambon USA Ltd.
• GlaxoSmithKline plc.

第13章 血尿治療市場-DataM

Market Overview

The global hematuria treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

The presence of blood in the urine can range from obvious to microscopic and undetectable. The presence of blood in a person's urine is known as hematuria. The most common cause of hematuria is urinary tract infections (UTIs).

Market Dynamics

The factors influencing the global hematuria treatment market are the increasing demand for treatment and the growing prevalence of hematuria treatment.

The increasing demand for treatment of hematuria is expected to drive the market growth

The presence of blood or blood cells in the urine is known as hematuria. Although blood in the urine is not always a sign of disease, it can be a crucial indicator of a potential health problem. Urine that is bloody should never be ignored. The treatment for hematuria is highly dependent on the cause of blood in the urine. The best treatment option is determined using the information gathered from the medical history, physical exam, and any test results. The incidence of hematuria is increasing, and people over the age of 35 are more likely to develop the symptoms of hematuria. According to information circulated by the International Incontinence Society, 70 percent to 80 percent of people over the age of 80 experience symptoms of overactive bladder function. Moreover, blood in the urine can occur for a variety of reasons, such as hepatitis, a virus that causes liver disease and inflammation, viral illness, such as hepatitis a virus that causes liver disease and inflammation, sexual activity, endometriosis, or menstrual endometriosis, in which the tissue that normally lines the uterus grows elsewhere, such as the bladder. Hence, with increasing reasons for hematuria, the demand for its treatment is expected to grow.

Lack of awareness is expected to hamper the market growth

Microscopic hematuria is a common condition that affects 9 to 18 percent of people who appear to be healthy. Mariani et al. looked at 1000 patients with hematuria and found that 9.1% had life-threatening lesions, but the disease was localized in 92 percent of the cases. Urinary bleeding has been linked to anticoagulants like aspirin and blood thinners. Furthermore, some anti-cancer drugs have been linked to this ailment. Familial idiopathic hematuria is a type of idiopathic hematuria that runs in families. When there is no family history of kidney failure, and all other medical tests come back negative, there is usually no need for treatment. Hence, with limited information and knowledge, the global hematuria treatment market is expected to be hampered.

COVID-19 Impact Analysis

The sudden outbreak of the fatal coronavirus pandemic has been a major source of concern for the global hematuria treatment market's operations and treatments in the current forecast period. The arrival of the pandemic has caused major disruptions in the global market's demand and supply chain mechanisms, and medical professionals are solely focused on treating patients who have succumbed to the pandemic's fatalities, which are followed by rising cases and non-stop waves of the pandemic of various infection variants. The operation theatres and other medical rooms prioritize the treatment of covid positive patients, and a team of doctors and other medical personnel is devoting their time and resources to this cause. Moreover, blood urea nitrogen (BUN), creatinine, uric acid, D-dimer levels, proteinuria, and hematuria are signs of kidney failure. According to a study on hospitalization, 60 percent of 147 COVID-19 patients developed proteinuria, and 48 percent had hematuria. Hence, covid-19 is expected to positively and negatively impact the market.

Segment Analysis

Microscopic Hematuria segment is expected to dominate the market growth

Microhematuria, or microscopic blood traces in the urine, can occur for various reasons, including strenuous exercise or kidney stones. Microhematuria is frequently discovered during routine testing rather than as a result of symptoms. Although microhematuria isn't contagious, the most common cause is a urinary tract infection (which isn't contagious either). When it comes to cancer and microhematuria, the chances are higher as one gets older and smokes or uses tobacco products. The cause determines the treatment for microscopic hematuria. If testing reveals no cause for microscopic hematuria, treatment may not be required, and observation may be advised. Antibiotics may be prescribed if a patient has a urinary tract infection. The doctor may prescribe medication to shrink the prostate, relax the bladder, or both if the patient has an enlarged prostate. Surgical treatment may be necessary in some cases. When three to five red blood cells per high-power field are visible, microscopic hematuria, a common finding on routine urinalysis in adults, is clinically significant. Microscopic hematuria has many causes, from minor irritations to life-threatening urinary tract neoplasm.

Moreover, adults with asymptomatic microscopic hematuria have a prevalence of 0.19 to 21%. Asymptomatic microscopic hematuria is common in women, but it is less likely to be linked to women's urinary tract cancer than in men. The strongest predictors of urologic cancer in women are over 60 years old, smoking history, and gross hematuria.

Geographical Analysis

North America region is expected to hold the largest market share in the global hematuria treatment market

The factors such as favorable medical reimbursement policies, recent FDA approvals, a large number of drugs in the pipeline, and a growing focus on reducing the number of undiagnosed hematuria cases, the availability of early treatment is expected to drive the market in this region.

Microscopic hematuria is a condition that affects between 2% and 31% of people in the United States of America. Individuals over the age of 60 and those with a current or previous smoking history have higher rates. Urologic cancer is diagnosed in only a small percentage of people with microhematuria. About 2% to 3% of those with hematuria have a urologic malignancy when asymptomatic populations are screened with dipstick and/or microscopy medical testing. Screening regularly is not advised. Individuals with risk factors who have multiple tests have a higher risk of urologic cancer.

Competitive Landscape

With mergers, acquisitions, and product launches, the global hematuria treatment market is moderately competitive. Some of the key players in the market are Johnson & Johnson, Cipla Ltd., Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co., Pfizer Inc., Aurobindo Pharma USA, Zambon USA Ltd., GlaxoSmithKline plc.

Teva Pharmaceuticals Industries Ltd.

Overview: Teva Pharmaceutical Industries Ltd., headquartered in Petah Tikva, Israel, is an Israeli multinational pharmaceutical company. Its primary business is generic drugs, but it also deals in active pharmaceutical ingredients and proprietary pharmaceuticals to a lesser extent.

Product Portfolio: Antibiotics commonly treat hematuria caused by a urinary tract infection (UTI). These antibiotics kill the bacteria causing the UTI, halting the bleeding. For instance, the company's amoxicillin tablets are a penicillin-class antibiotic used to treat ear, nose, throat, and genitourinary tract infections caused by susceptible strains of microorganisms.

Why Purchase the Report?

Visualize the composition of the global hematuria treatment market segmentation by type, disease type, and end user, highlighting the key commercial assets and players.

identify commercial opportunities in global hematuria treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global hematuria treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global hematuria treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Hematuria Treatment Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Hematuria Treatment Market- Market Definition and Overview

3. Hematuria Treatment Market- Executive Summary

• 3.1. Market Snippet By Type
• 3.2. Market Snippet By Disease Type
• 3.3. Market Snippet By End User
• 3.4. Market Snippet By Region

4. Hematuria Treatment Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. The increasing demand for treatment of hematuria
  • 4.1.2. Restraints:
    • 4.1.2.1. Lack of awareness
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Hematuria Treatment Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs

6. Hematuria Treatment Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Hematuria Treatment Market- By Type

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
• 7.3. Market Attractiveness Index, By Type
  • 7.3.1. Drugs
    • 7.3.1.1.1. Introduction
    • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.3.1.1.3. Quinolones
    • 7.3.1.1.4. Penicillin & combinations
    • 7.3.1.1.5. Cephalosporin
    • 7.3.1.1.6. Nitrofurans
    • 7.3.1.1.7. others
  • 7.3.2. Therapies

8. Hematuria Treatment Market-By Disease Type

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
• 8.3. Market Attractiveness Index, By Disease Type
  • 8.3.1. Microscopic Hematuria
    • 8.3.1.1.1. Introduction
    • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3.2. Gross Hematuria

9. Hematuria Treatment Market- By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Specialty Clinics
• 9.4. Other

10. Hematuria Treatment Market- By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Hematuria Treatment Market- Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Hematuria Treatment Market- Company Profiles

• 12.1. Teva Pharmaceuticals Industries Ltd.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Johnson & Johnson
• 12.3. Cipla Ltd.
• 12.4. F.Hoffmann La Roche Ltd.
• 12.5. Merck & Co.
• 12.6. Pfizer Inc.
• 12.7. Aurobindo Pharma USA
• 12.8. Zambon USA Ltd.
• 12.9. GlaxoSmithKline plc.

LIST NOT EXHAUSTIVE

13. Hematuria Treatment Market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us